Bench to bedside of CTLA-4: A novel immuno-therapeutic agent for inflammatory disorders

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 3, Issue 2, 2009, Pages 84-95

  Sakthivel, Priya ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Abatacept; Co stimulatory molecules; CTLA 4; Inflammation; Multiple sclerosis; Psoriasis vulgaris; Rheumatoid arthritis

Indexed keywords

ABATACEPT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; METHOTREXATE; PLACEBO; ANTIBODY CONJUGATE; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; LEUKOCYTE ANTIGEN;

ANTIGEN PRESENTING CELL; BINDING COMPETITION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; IMMUNOTHERAPY; INFLAMMATORY DISEASE; MONOTHERAPY; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PSORIASIS VULGARIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PSORIASIS; T LYMPHOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC; PSORIASIS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 68949194394     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221309788489805     Document Type: Review

References (99)

1. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970; 169: 1042-1049.
2. Lafferty KJ, Woolnough J. The origin and mechanism of the allograft reaction. Immunol Rev 1977; 35: 231-262.
3. Jenkins MK, Ashwell JD, Schwartz RH. Allogeneic non-T spleen cells restore The unresponsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J Immunol 1988; 140: 3324-3330.
4. Jansson A, Barnes E, Klenerman P, et al. A theoretical framework for quantitative analysis of the molecular basis of co-stimulation. J Immunol 2005; 175: 1575-1585.
5. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992; 356: 607-609.
6. Fraser JD, Irving BA, Crabtree GR, Weiss A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991; 251: 313-316.
7. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995; 3: 87-98.
8. Van der Merwe PA, Davis SJ. Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol 2003; 21: 659-684.
9. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cells activation. Immunity 1994; 1: 405-413.
10. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-mediated inhibition of earlyevents of T cell proliferation. J Immunol 1999; 162: 5813-5820.
11. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 Family revisited. Annu Rev Immunol 2005; 23: 515-548.
12. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005; 23: 23-48.
13. Dariavach P, Mattei H-G, Golstein P, Lefranc M-P. Human Ig superfamily CTLA-4 gene: Chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol 1988; 18: 1901-1905.
14. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561-569.
15. Harper K, Balzano C, Rouvier E, Mattei M-G, Luciani M-F, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure and chromosomal location. J Immunol 1991; 147: 1037-1044.
16. Balzano C, Buonavista N, Rouvier E, Golstein P. CTLA-4 and CD28: Similar protein, neighbouring genes. Int J Cancer Suppl 1992; 7: 28-32.
17. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the Response of T cells to stimulation. J Exp Med 1995; 182: 459-465.
18. Linsley PS, Nadler SG, Bajorath J, et al. Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4): A disulfide-linked homodimer binds two CD86 molecules. J Biol Chem 1995; 270: 15417-15424.
19. Magistrelli G, Jeannin P, Herbault N, et al. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999; 29: 3596-3602.
20. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1(CD80) and B7-2(CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994; 1(9): 793-801.
21. Vijayakrishnan L, Slavik JM, Illés Z, et al. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 2004; 20(5): 563-575.
22. Waterhouse P, Penninger JM, Timms E, et al. Lympho-proliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995; 270(5238): 985-988.
23. Karandikar NJ, Vanderlungt CL, Walunasv TL, Miller SD, Bluestone JA. CTLA-4: A negative regulator of autoimmune diseases. J Exp Med 1996; 184(2): 783-788.
24. Kouki T, Sawai Y, Gardine CA, Fisfalen M-E, Alegre M-L, DeGroo LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000; 165: 6606-6611.
25. Djilali-Saiah I, Schmitz J, Harfouch-Hammoud E, Mougenot J-F, Bach J-F, Caillat-Zucman S. CTLA-4 gene polymorphism is associated with predisposition to coeliac disease. Gut 1998; 43: 187-189.
26. Hans S, Li Y, Mao Y, Xie Y. Meta-analysis of the association of CTLA-4 exon-1 +49A/G polymorphism with rheumatoid arthritis. Hum Genet 2005; 118 (1): 123-132.
27. Lee YH, Harley JB, Nath SK. CTLA-4 polymorphisms and systemic lupus eryhtematosus (SLE): A meta-analysis. Hum Genet 2005; 116(5): 361-367.
28. Ueda H, Howson JMM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-511.
29. Van Belzen MJ, Mulder CJ, Zhernakova A, Pearson PL, Houwen RH, Wijmenga C. CTLA-4 +49 A/G and CT60 polymorphisms in Dutch celiac disease patients. Eur J Hum Genet 2004; 12(9): 782-785.
30. Mayans S, Lackovic K, Nyholm C, et al. CT60 genotype does not affect CTLA-4 isoform expression despite association to T1D and AITD in northern Sweden. BMC Med Genet 2007; 8: 3.
31. Kavvoura FK, Akamizu T, Awata T, et al. Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: A meta-analysis. J Clin Endocrinol Metab 2007; 92(8): 3162-3170.
32. Concannon P, Erlich HA, Julier C, et al. Type 1 diabetes: Evidence for susceptibility loci from four genome-wide linkage scans in 1,435 multiplex families. Diabetes 2005; 54 (10): 2995-3001.
33. Petrone A, Giorgi G, Galgani A, et al. CT60 single nucleotide polymorphisms of the cytotoxic-T lymphocyte-associated antigen-4 gene region is associated with Grave's disease in an Italian population. Thyroid 2005; 15(3): 232-238.
34. Lei C, Dongqing Z, Yeqing S, et al. Association of the CTLA-4 gene with rheumatoid arthritis in Chinese Han population. Eur J Hum Genet 2005; 13: 823-828.
35. Downie-Doyle S, Bayat N, Rischmueller M, Lester S. Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjogren syndrome. Arthrtis Rheum 2006; 54(8): 2434-2440.
36. Donner H, Braun J, Seidl C, et al. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. J Clin Endocrinol Metab 1997; 82: 4130-4132.
37. Krokowski M, Bodalski J, Bratek A, Machejko P, Caillat-Zucman S. CTLA-4 gene polymorphism is associated with predisposition to IDDM in a population from central Poland. Diabetes Metab 1998; 24: 241-243.
38. Pullmann R Jr, Lukac J, Skerenova M, et al. Cytotoxic T lymphocyte antigen 4 (CTLA-4) dimorphism in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1999; 17: 725-729.
39. Ligers A, Xu C, Saarinen S, Hillert J, Olerup O. The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol 1999; 97: 182-190.
40. Yanagawa T, Gomi K, Nakao EI, Inada S. CTLA-4 gene polymorphism in Japanese patients with rheumatoid arthritis. J Rheumatol 2000; 27: 2740-2742.
41. Kamoun AH, Hmida S, Smaoui N, et al. Association between type 1 diabetes and polymorphism of the CTLA-4 gene in a Tunisian population. Pathol Biol (Paris) 2001; 49: 794-798.
42. Kalantari T, Mostafavi H, Pezeshki AM, et al. Exon-1 polymorphism of ctla-4 gene in Iranian patients with Graves' disease. Autoimmunity 2003; 36: 313-316.
43. Pavkovic M, Georgievski B, Cevreska L, Spiroski M, Efremov DG. CTLA-4 exon 1 polymorphism in patients with autoimmune blood disorders. Am J Hematol 2003; 72: 147-149.
44. Hudson LL, Silver RM, Pandey JP. Ethnic differences in cytotoxic T lymphocyte associated antigen 4 genotype associations with systemic sclerosis. J Rheumatol 2004; 31: 85-87.
45. Chang MC, Chang YT, Tien YW, et al. T-cell regulatory gene CTLA-4 polymorphism/haplotype association with autoimmune pancrea-titis. Clin Chem 2007; 53: 1700-1705.
46. Du L, Yang P, Hou S, et al. Association of the CTLA-4 gene with Vogt-Koyanagi-Harada syndrome. Clin Immunol 2008; 127(1): 43-48.
47. Pavlova A, Diaz-Lacava A, Zeitler H, et al. Increased frequency of the CTLA-4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls. Haemophilia 2008; 14(2): 355-360.
48. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab 1995; 80: 41-45.
49. Kotsa K, Watson PF, Weetman AP. A CTLA-4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism. Clin Endocrinol (Oxf) 1997; 46: 551-554.
50. Huang D, Giscombe R, Zhou Y, Lefvert AK. Polymorphisms in CTLA-4 but not tumor necrosis factor-alpha or interleukin 1beta genes are associated with Wegener's granulomatosis. J Rheumatol 2000; 27: 397-401.
51. Djilali-Saiah I, Ouellette P, Caillat-Zucman S, Debray D, Kohn JI, Alvarez F. CTLA-4/CD 28 region polymorphisms in children from families with autoimmune hepatitis. Hum Immunol 2001; 62: 1356-1362.
52. Hudson LL, Rocca K, Song YW, Pandey JP. CTLA-4 gene polymorphisms in systemic lupus erythematosus: A highly significant association with a determinant in the promoter region. Hum Genet 2002; 111: 452-455.
53. Luo Y, Xia B, Li C, et al. Cytotoxic T lymphocyte antigen-4 promoter -658CT gene polymorphism is associated with ulcerative colitis in Chinese patients. Int J Colorectal Dis 2009 [Epub ahead of print].
54. Sakthivel P, Shively VP, Kakoulidou M, Pearce W, Lefvert AK. The soluble forms of CD28, CD86 and CTLA-4 constitute possible immunological markers in patients with abdominal aortic aneurysm. J Intern Med 2007; 261(4): 399-407.
55. Wang XB, Kakoulidou M, Giscombe R, et al. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: Effect of an AT-rich gene sequence. J Neuroimmunol 2002; 130: 224-232.
56. Liu MF, Wang CR, Chen PC, Fung LL. Increased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus. Scand J immunol 2003; 57(6): 568-572.
57. Sato S, Fujimoto M, Hasegawa M, et al. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 2004; 43: 1261-1266.
58. Wong CK, Lun SW, Ko FW, Ip WK, Hui DS, Lam CW. Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma. Clin Exp Immunol 2005b; 141: 122-129.
59. Ip WK, Wong CK, Leung TF, Lam CW. Elevation of plasma soluble T cell costimulatory molecules CTLA-4, CD28 and CD80 in children with allergic asthma. Int Arch Allergy Immunol 2005; 137: 45-52.
60. Luszczek W, Kubicka W, Jasek M, et al. CTLA-4 gene polymorphisms and natural soluble CTLA-4 protein in Psoriasis vulgaris. Int J Immunogenet 2006; 33: 217-224.
61. Saverino D, Brizzolara R, Simone R, et al. Soluble CTLA-4 in autoimmune thyroid diseases: Relationship with clinical status and possible role in the immune response dysregulation. Clin Immunol 2007; 123: 190-198.
62. Engelhardt JJ, Sullivan TJ, Allison JP. CTLA-4 overexpression inhibits T cell responses through a CD28-B7 dependent mechanism. J Immunol 2006; 177(2): 1052-1061.
63. Stamper CC, Zhang Y, Tobin JF, et al. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 2001; 410: 608-611.
64. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3(11): 1097-1101.
65. Schneider H, Downey J, Smith A, et al. Reversal of the TCR stop signal by CTLA-4. Science 2006; 313 (5795): 1972-1975.
66. Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ. A native soluble form of CTLA-4. Cell Immunol 2000; 201: 144-153.
67. Hebbar M, Jeannin P, Magistrelli G, et al. Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjogren's syndrome and systemic sclerosis. Clin Exp Immunol 2004; 136: 388-392.
68. Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Eng J Med 1996; 335: 1369-1377.
69. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998; 338: 1813-1821.
70. Lenschow DJ, Zeng Y, Thistlethwaite J, et al. Long-term survival of xenogeneic pancreatic islets grafts induced by CTLA-4Ig. Science 1992; 257: 789-792.
71. Wang Q, Zhang M, Ding G, et al. Anti-ICAM-1 antibody and CTLA-4Ig synergistically enhance immature dendritic cells to induce donor-specific immune tolerance in vivo. Immunol Lett 2003; 90(1): 33-42.
72. Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12(4): 431-440.
73. Boden E, Tang Q, Bour-Jordan H, Bluestone JA. The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells. Novartis Found Symp 2003; 252: 55-63.
74. Panayi GS, Corrigall VM, Pitzalis C. Pathogenesisbof rheumatoid arthritis. The role of T cells and other beasts. Rheum Dis Clin North Am 2001; 27: 317-334.
75. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006; 10(42): iii-iv, xi-xiii, 1-229.
76. Ostor AJK. Abatacept: A T cell costimulation modulator for the treatment of rheumatoid arthritis. Clin Immunol 2008; 27: 1343-1353.
77. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349(20): 1907-1915.
78. Package Leaflet. Orencia (Abatacept) Princeton. NJ: Bristol-Myer Squibb Co. December 2005.
79. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med 2006; 144(12): 865-876.
80. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353(11): 1114-1123.
81. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 2006; 54(9): 2807-2816.
82. Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomized clinical trial. Ann Rheum Dis 2007; 66(2): 228-234.
83. Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dosefinding, double blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002; 46 (6): 1470-1479.
84. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: A phase III, multicentre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008; 67(8): 1096-1103.
85. Sherrar Y. Abatacept in biologic-naïve patients and TNF inadequate responders: Clinical data in focus. Curr Res Med Opin 2008; 24(8): 2283-2294.
86. Traugott U, Reinherz EL, Raine CS. Multiple sclerosis: Distribution of T cell subsets within active chronic lesions. Science 1983; 219(4582): 308-310.
87. Furtado GC, Piña B, Tacke F, et al. A novel model of demyelinating encephalomyelitis induced by monocytes and dendritic cells. J Immunol 2006; 177(10): 6871-6879.
88. Viglietta V, Bourcier K, Buckle GJ, et al. CTLA4Ig treatment in patients with multiple sclerosis: An open-label, phase 1 clinical trial. Neurology 2008; 71: 917-924.
89. Schlaak JF, Buslau M, Jochum W, et al. T cells involved in Psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994; 102(2): 145-149.
90. Judith R, Abrams, Mark G, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with Psoriasis vulgaris. J Clin Invest 1999; 103(9): 1243-1252.
91. Thompson, C.B., June, C.H.: US20080305092 (2008).
92. Gottlieb AB, Kang S, Linden KG, et al. Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to sever plaque psoriasis. Clin Immunol 2004: 111(1): 28-37.
93. Anderson, D.R., Hanna, N., Brams, P.: US20077175847 (2007).
94. Srinivasan M, Wardrop RM, Gienapp IE, Stuckman SS, Whitacre CC, Kaumaya PT. A retro-inverso peptide mimic of CD28 encompassing the MYPPY motif adopts a polyproline type II helix and inhibits encephalitogenic T cells in vitro. J Immunol 2001; 167 (1): 578-585.
95. Srinivasan M, Gienapp IE, Stuckman SS, et al. Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28. J Immunol 2002; 169(4): 2180-2188.
96. Kaumaya, P.T.P., Whitacre, C.C., Srinivasan, M.: US20077220822 (2007).
97. Futamatsu H, Suzuki J, Kosuge H, et al. Attenuation of experimental autoimmune myocarditis by blocking activated T cells through inducible costimulatory molecule pathway. Cardiovasc Res 2003; 59(1): 95-104.
98. Katsumata Y, Harigai M, Sugiura T, et al. Attenuation of experimental autoimmune myositis by blocking ICOS-ICOS ligand interaction. J Immunol 2007; 179(6): 3772-3779.
99. Coyle, A., Yao, Y., Jallal, B., Carlesso, G., Bowen, M.: US20080279851 (2008).